Emergent Biosolutions (EBS) Stock Price, News & Analysis

Company Overview

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal. The company invests in research and development to expand its pipeline of vaccines and therapeutics, with particular emphasis on next-generation platforms and novel delivery approaches.

Emergent operates research, development and manufacturing facilities in North America, Europe and Asia. Its primary U.S. manufacturing sites in Maryland and Michigan produce both licensed products and countermeasures under contract, while additional sites and partnerships support global distribution. Through a network of collaborations and supply agreements, Emergent serves government health agencies, commercial customers and international markets to ensure availability of its critical medical products.

Founded in 1998 (originally as BioPort) and renamed Emergent BioSolutions in 2004, the company is led by President and Chief Executive Officer Robert G. Kramer Jr. Under his leadership, Emergent has expanded its contract manufacturing footprint, strengthened its commercial portfolio and advanced strategic initiatives in pandemic preparedness. The company remains focused on leveraging its expertise in biodefense and public health to address evolving global health challenges.

Key Stats

• Today's Range: $7.88 to $8.29
• 50-Day Range: $5.63 to $9.30
• 52-Week Range: $4.02 to $12.73
• Volume: 908,494 shs
• Average Volume: 956,560 shs
• Market Capitalization: $425.73 million
• P/E Ratio: 3.26
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Buy

Emergent Biosolutions Stock Analysis - MarketRank™

Emergent Biosolutions scored higher than 96% of companies evaluated by MarketBeat, and ranked 61st out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Emergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Emergent Biosolutions has a consensus price target of $13.50, representing about 69.2% upside from its current price of $7.98.

Amount of Analyst Coverage

Emergent Biosolutions has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Emergent Biosolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Emergent Biosolutions is 3.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of Emergent Biosolutions is 3.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.08.

Price to Book Value per Share Ratio

Emergent Biosolutions has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.06% of the float of Emergent Biosolutions has been sold short.

Short Interest Ratio / Days to Cover

Emergent Biosolutions has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Emergent Biosolutions has recently decreased by 11.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Emergent Biosolutions does not currently pay a dividend.

Dividend Growth

Emergent Biosolutions does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.40

Percentage of Shares Shorted

17.06% of the float of Emergent Biosolutions has been sold short.

Short Interest Ratio / Days to Cover

Emergent Biosolutions has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Emergent Biosolutions has recently decreased by 11.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.07

News Sentiment

Emergent Biosolutions has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Emergent Biosolutions this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

4 people have added Emergent Biosolutions to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $130,703.00 in company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Emergent Biosolutions is held by insiders.

Percentage Held by Institutions

78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EBS Stock Analysis - Frequently Asked Questions

How have EBS shares performed this year?

Emergent Biosolutions' stock was trading at $9.56 at the start of the year. Since then, EBS shares have decreased by 16.5% and is now trading at $7.98.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc. (NYSE:EBS) released its quarterly earnings data on Wednesday, August, 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.42. The biopharmaceutical company had revenue of $140.90 million for the quarter, compared to analyst estimates of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a trailing twelve-month return on equity of 24.63%.
Read the conference call transcript.

Is Emergent Biosolutions doing a stock buyback?

Emergent Biosolutions' Board of Directors approved a stock buyback plan on Monday, March 31st 2025, which permits the company to repurchase $50,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 19% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

Who are Emergent Biosolutions' major shareholders?

Top institutional shareholders of Emergent Biosolutions include American Century Companies Inc. (4.30%), Geode Capital Management LLC (2.36%), Palisade Capital Management LP (2.06%) and Marshall Wace LLP (1.91%). Insiders that own company stock include Donald W Degolyer, Neal Franklin Fowler, Keith Katkin, Kathryn C Zoon and Ronald Richard.
View institutional ownership trends.

How do I buy shares of Emergent Biosolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:EBS
• CIK: 1367644
• Web: www.emergentbiosolutions.com
• Phone: (240) 631-3200
• Fax: 301-795-1899
• Employees: 2,420
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Emergent Biosolutions: $13.50
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +69.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.45
• Trailing P/E Ratio: 3.26
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.60 million
• Net Margins: 16.38%
• Pretax Margin: 22.39%
• Return on Equity: 24.63%
• Return on Assets: 8.97%

Debt

• Debt-to-Equity Ratio: 1.25
• Current Ratio: 5.66
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: $1.04 billion
• Price / Sales: 0.41
• Cash Flow: $1.88 per share
• Price / Cash Flow: 4.24
• Book Value: $8.91 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 53,350,000
• Free Float: 51,644,000
• Market Cap: $425.73 million
• Optionable: Optionable
• Beta: 2.03